Sanofi and Regeneron are expanding their immunology alliance to develop and commercialize four Regeneron-invented, long-acting antibodies targeting type 2 inflammation, extending their collaboration beyond Dupixent. The lead candidate, REGN20423, is a Phase 1 IL-13 antibody being studied for atopic dermatitis; the other programs target IL-4, IL-4 receptor alpha, and IL-4 and IL-13 together. Regeneron will receive $1 billion upfront and could earn up to $7 billion in development, regulatory, and commercial milestones. The companies will share development and commercialization costs equally and split profits from any new products 50-50, while leaving their existing Dupixent arrangement unchanged. The expanded pipeline is intended to help the partners build on Dupixent’s success and prepare for the years ahead as the drug approaches patent expiry in the 2030s.
Where do you stand?
How it spread
What each side asserts, disputes — or leaves out entirely.
Whose framing of this story rings truest to you?
Left· 0 sources
No left coverage yet — a bubble gap.
Sanofi is betting big on Regeneron's platform with that upfront cash, but sharing profits equally should keep both sides motivated on the new antibodies.
